Product Images Regen-cov

This appears to be a table showing the results of a study evaluating the effects of different treatments on viral load change in patients. The treatments evaluated were placebo, REGEN-COV 1.2g IV and REGEN-COV 24g IV. The table shows the mean viral load change in log10 scale and the number of patients in each treatment group. No further information is available.*

This is a product description for the medication Casirivimab, which is obtained under Emergency Use Authorization (EUA). It is an Intravenous Infusion medication that must be administered only with Imdevimab. The medication is available in a single-dose injection form, with an NDC number of 61755-026-00. It is manufactured by Regeneron Pharmaceuticals. The text includes a LOT/EXP number, but it is not clearly readable.*

This is a description of a medication called "Casirivimab" in the form of a concentrate for solution for infusion. It has a concentration of 120 mg/mL and must be administered with "imdevimab" intravenously after dilution. The medication is registered under "Lot EXP" and the manufacturer's name is "EECTZENIT s>".*

This is a description for a medical product called "Caslrivimab Injection." It is a drug that comes in 300mg/2.5mL dosage (120mg/mL) meant for intravenous infusion after dilution. The drug must be used under Emergency Use Authorization (EUA) and should be administered with Imdevimab. The package contains a single-dose vial, and unused portions should be discarded. "GIENED Rotorto DA Authorzed actShects yscaming e OR ode EEQ Uneicaconon" and other -generated text are not available for use in the description.*

This is a solution for intravenous infusion or subcutaneous injection with a subject number. It should be administered in accordance with protocol instructions and stored refrigerated at 2°C-8°C in the original carton to protect from light. It is cautioned to keep out of reach of children and is for clinical trial use only. The drug is new and limited by federal laws to investigational use. The product is made by Regeneron Pharmaceuticals located in Tarrytown, New York. The drug is labeled REGN10933 and is 300 MG/2.5ML.*

Subject Number, Investigator, and Dispensed Date are provided in the text, but the rest of the text seems to be related to a medication called "vl Scluto" and its instructions for use. It should be stored in a cool place and kept away from children. There is also a caution mentioning that it's a new drug and is regulated by federal law. It seems like an information insert for the medication.*

Casirivimab is an injection that requires a prescription and has a National Drug Code (NDC) of 61755-024-00. It is intended for intravenous infusion after dilution and to be used only under Emergency Use Authorization (EUA). It must be administered with IMDEVIMAB. The manufacturer is Regeneron Pharmaceuticals, Inc. The other information available is not clear and seems to be an error in the process.*

Casirivimab is a concentrate for a solution for infusion. The concentration is 120 mg/mL with a quantity of 1332 mg/11.1 mL IV after dilution. It is necessary to administer it with imdevimab. No further information is available.*

This is a description of Casirivimab Injection, a single-dose vial of intravenous infusion for emergency use only after dilution. It contains 1332 mg/11.1 mL (120 mg/mL) of Casirivimab, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose, and water for injection, USP with a pH of 6. The injection must be administered with Imdevimab, and any unused portion should be discarded. The original package should be stored between 2°C to 8°C (36°F to 46°F), and the detailed preparation and administration instructions are available on the FDA-authorized fact sheet, which can be accessed by scanning the given QR code. Do not freeze, shake, or use if the vial is broken or if the solution appears to be cloudy or discolored. The text also contains a few address details, but they are not useful in describing the product.*

Casirivimab is a medication with National Drug Code (NDC) 61755-024-01. No other information is available.*

This is a solution for intravenous administration with a subject number of REGN10933, administered by following protocol instructions. It should be stored refrigerated at 2°C—8°C (36°F—46°F) in its original carton to protect it from light. It is intended for clinical trial use only and is a new drug that is limited by Federal (or United States) law for investigational use. The manufacturer is Regeneron Pharmaceuticals, located in Tarrytown, NY 10591 USA, and it should be kept out of reach of children. The solution contains 120mg/mL.*

This is a product description that provides information on Imdevimab, an injection for intravenous infusion after dilution. It has a concentration of 300mg/2.5mL and is available with NDC code 61755-027-00. The product is meant to be used under Emergency Use Authorization (EUA) and must be administered with Casirivimab. The manufacturer is Regeneron Pharmaceuticals, and the LOT/EXP number is not available.*

This text is a product label for Imdevimab concentrate, which is intended for intravenous (IV) infusion after dilution. The concentration of the solution is 120 mg/mL, and it must be administered with Casirivimab. The lot and expiration date of the product are not provided.*

This is information about Imdevimab, a medication produced by Pharmaceuticals, Inc. that comes in a 300mg/2.5mL (120mg/mL) dosage. It has an NDC number of 61755-027-01. The text does not provide any further information.*

This is a description of a clinical trial drug labeled as "REGN10987". It is a solution for intravenous infusion or subcutaneous injection and must be administered following protocol instructions. The drug needs to be stored refrigerated at temperatures ranging from 2°C to 8°C (36°F-46°F) in its original carton to prevent light exposure. The drug is limited for investigational use only, and therefore caution should be taken when handling it. The drug is produced by Regeneron Pharmaceuticals, Inc., and the company can be contacted at +1 914-847-7000. The concentration of the drug is 300mg/2.5ml (120mg/mL).*

Imdevimab is a prescription injection that comes with a National Drug Code (NDC) of 61755-025-00. It has a strength of 1332 mg/11.1 mL (120 m) and is meant to be administered intravenously after dilution. This medication is for emergency use only and is eligible for use under the Emergency Use Authorization (EUA). It should only be administered with Casirivimab. Imdevimab is manufactured by Regeneron Pharmaceuticals, Inc.*

This is a medication called Imdevimab 120mg/mL, which is a concentrate for solution for infusion. The provided information includes the amount of Imdevimab in milligrams and mililiters, as well as instructions to administer it intravenously after dilution. It also mentions that it should be administered with another medication called Casirivimab, and provides a code of 10238452 IE (£).*

This is a description of a pharmaceutical product from Regeneron Pharmaceuticals, with the subject number REGN10987. The product is a solution for intravenous administration and should be stored refrigerated at 2°C—8°C. It is limited by federal law for investigational use in clinical trials and should be kept out of reach of children. The provided contact information for Regeneron Pharmaceuticals is +1 914-847-7000, located in Tarrytown, NY 10591 USA. The concentration of the solution is 120 MG/ML.*

REGEN-COV is a prescription medication with the active ingredients casirivimab and imdevimab. It is available in a single-dose vial containing 600mg/600mq per 10mL (60 mg/60 mg per mL) for injection. The medication is only for emergency use authorization and is manufactured by Regeneron Pharmaceuticals, Inc. Unused medication should be discarded.*

REGEN-COV is an injection containing 600 mg of casirivimab and 600 mg of imdevimab, which should be stored in the original carton in a refrigerator between 2°C to 8°C. The injection is administered using detailed instructions on dosage, preparation, and route of administration, available through a QR code scan or on the website www.REGENCOV.com. The injection is for use under Emergency Use Authorization (EUA) for treating COVID-19 with no standard of potency. It is a sterile solution and should not be shaken, used if broken or missing, or frozen. Each vial contains 10 mL of solution, of which the unused portion must be discarded.*

This is a description of a dose pack of REGEN-COV, a medicine that treats COVID-19. The pack contains two vials, one with casirivimab (1332 mg/1.1 mL) and the other with imdevimab (1332 mg/11.1 mL). The two must be diluted and administered intravenously together. The pack should be stored in a refrigerator between 2°C and 8°C and should not be frozen. The pack comes with a lot number, and the manufacturer's phone number is included. Detailed preparation and administration instructions are available on an FDA-authorized fact sheet.*

This is a dose pack for REGEN-COV™ which contains casirivimab and imdevimab. It is a complete dose and must be diluted and administered only via intravenous infusion. This is for use under Emergency Authorization (EUA). The dose pack comes with four vials of each component and must be stored refrigerated between 2°C - 8°C (36 F to 46°F). Details on dosing and administration can be found on the FDA-authorized Fact Sheet. The pack should not be opened until the time of dose preparation and should not be frozen. The lot number for the dose pack is not available.*

This is a dose pack of REGEN-COV™, containing four vials of imdevimab, each with a strength of 300 mg/2.5 mL (120 mg/mL), and must be diluted and administered intravenously. The product is intended for use under emergency authorization and comes with a fact sheet for detailed preparation. The dose pack should be stored refrigerated between 2°C - 8°C and should not be frozen. This is a product of Regeneron and its lot number is provided. The barcode is for manufacturer's internal use only and contact info for the company is provided.*

This is a description of a dose pack for REGEN-COV, which is a treatment for COVID-19 under emergency authorization. The pack includes 4 vials of casirivimab and 1 vial of imdevimab, which must be diluted and administered together via intravenous infusion. The pack should be refrigerated between 2°C - 8°C (36 °F to 46°F) and is not to be opened until time of dose preparation. For detailed preparation and administration instructions, refer to the FDA-authorized Fact Sheet. Lot number and manufacturer's contact details are provided.*

Casilimab and Imdevimab are combined to make a single intravenous infusion for pandemic use. Each vial contains 1332 mg/11.1 mL of the respective ingredient. The concentrate is intended for intravenous use only after dilution and must be used immediately after opening. It should be kept out of the reach of children and should be stored in a refrigerator between 2°C to 8°C. Read the package leaflet before using the medicinal product. The text also includes a German address and phone number.*

Casirivimab and Imdevimab 120 mg/mL is a concentrate for a solution meant for infusion after dilution. There are two vials of 6 mL each available for intravenous use. The manufacturer is Roche Pharma AG, located in Germany. No other relevant information is available.*